Probiotic Enterococcus Transcriptome Mining Yields Potent AMP Against XDR Bacteria
Computational mining of Enterococcus transcriptomes identified 14 candidate AMPs, with EM_4 showing potent activity (MIC 2.5-20 μM) against susceptible and XDR S. aureus and A. baumannii with low hemolysis.
Quick Facts
What This Study Found
EM_4: MIC 2.5-20 μM against susceptible and XDR S. aureus/A. baumannii; MBC 5-20 μM; antibiofilm 40-80 μM; 3.2% hemolysis; thermostable and salt-stable; membrane-disrupting mechanism.
Key Numbers
How They Did This
Transcriptome mining of Enterococcus species, computational AMP prediction and filtering, synthesis of EM_4, MIC/MBC, stability testing, antibiofilm assays, hemolysis, and DNA-release mechanism studies.
Why This Research Matters
XDR infections cause thousands of deaths with few treatment options. Mining commensal bacteria for AMPs exploits a co-evolutionary relationship between host and microbiome.
The Bigger Picture
Probiotic bacteria have co-evolved antimicrobial defenses that could be harnessed as next-generation antibiotics against the most dangerous resistant pathogens.
What This Study Doesn't Tell Us
In vitro only. Single lead peptide validated. In vivo efficacy and toxicity not tested.
Questions This Raises
- ?Would EM_4 be effective in animal XDR infection models?
- ?Could other Enterococcus-derived AMPs complement EM_4's spectrum?
- ?Is the low hemolysis maintained at therapeutic concentrations in vivo?
Trust & Context
- Key Stat:
- 2.5 μM MIC vs XDR EM_4 kills extensively drug-resistant bacteria at very low concentrations with only 3.2% hemolysis
- Evidence Grade:
- Well-executed computational-to-experimental pipeline with comprehensive in vitro validation. Novel AMP source.
- Study Age:
- Published in 2025.
- Original Title:
- Exploration of Novel Antimicrobial Peptides from Gut Probiotics Enterococcus spp. Against Extensively drug-resistant Pathogens Through cutting-edge Computational Discovery.
- Published In:
- Probiotics and antimicrobial proteins (2026)
- Authors:
- Hasannejad-Asl, Behnam, Bagheri, Kamran Pooshang(2), Bandehpour, Mojgan, Bolhassani, Azam, Hashemi, Ali, Pooresmaeil, Farkhondeh, Kazemi, Bahram
- Database ID:
- RPEP-15269
Evidence Hierarchy
Frequently Asked Questions
Can gut bacteria provide new antibiotics?
Yes. Probiotic Enterococcus bacteria naturally produce antimicrobial peptides. This study found one (EM_4) that kills even the most resistant hospital bacteria at very low concentrations.
Why is 3.2% hemolysis important?
Hemolysis measures red blood cell damage. At only 3.2%, EM_4 is very safe for blood cells while being lethal to bacteria — a favorable therapeutic index.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15269APA
Hasannejad-Asl, Behnam; Bagheri, Kamran Pooshang; Bandehpour, Mojgan; Bolhassani, Azam; Hashemi, Ali; Pooresmaeil, Farkhondeh; Kazemi, Bahram. (2026). Exploration of Novel Antimicrobial Peptides from Gut Probiotics Enterococcus spp. Against Extensively drug-resistant Pathogens Through cutting-edge Computational Discovery.. Probiotics and antimicrobial proteins. https://doi.org/10.1007/s12602-026-10919-w
MLA
Hasannejad-Asl, Behnam, et al. "Exploration of Novel Antimicrobial Peptides from Gut Probiotics Enterococcus spp. Against Extensively drug-resistant Pathogens Through cutting-edge Computational Discovery.." Probiotics and antimicrobial proteins, 2026. https://doi.org/10.1007/s12602-026-10919-w
RethinkPeptides
RethinkPeptides Research Database. "Exploration of Novel Antimicrobial Peptides from Gut Probiot..." RPEP-15269. Retrieved from https://rethinkpeptides.com/research/hasannejad-asl-2026-exploration-of-novel-antimicrobial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.